Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
MG-132 (Z-LLL-al): Proteasome Inhibitor Guide
2026-09-04
MG-132, also called Z-LLL-al, is a membrane-permeable peptide aldehyde that inhibits proteasome-dependent protein degradation. Its reported effects include protein accumulation, oxidative stress and ROS generation, cell cycle arrest, and apoptosis, making it useful for mechanistic cancer research rather than clinical treatment.
-
Leptin Signaling Meets Immunometabolic Translation
2026-09-04
Leptin (116-130), amide, mouse, offers translational researchers a defined peptide probe for connecting energy homeostasis regulation with inflammatory biology. This article interprets the fragment alongside evidence that berberine activates SIRT6–AMPK signaling and suppresses NLRP3 inflammasome activity in angiotensin II-induced atrial remodeling. The result is a practical framework for testing metabolic–inflammatory hypotheses without overstating what the current evidence proves.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding
2026-09-03
Oliveira and colleagues report that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike protein binding to host receptors, with especially strong effects observed for selected N-terminally truncated peptides. The study provides a structure–activity framework for connecting renin-angiotensin system research with viral-entry assays while emphasizing that binding results require validation in cellular and in vivo models.
-
Solanesol: Practical Hydrophobic Assay Guide
2026-09-03
Solanesol (SKU B8776) provides a defined polyisoprenoid alcohol for biochemical and membrane-related workflows that require controlled handling of a hydrophobic compound. It should be prepared in DMSO and used with solvent-matched controls; it is insoluble in water and ethanol and is not intended for diagnostic, clinical, or medical use.
-
Angiotensin 1/2 (1-6): Research Guide
2026-09-02
Angiotensin 1/2 (1-6) is an Asp-Arg-Val-Tyr-Ile-His hexapeptide used to examine renin-angiotensin system biology. Evidence from a 2025 binding study shows that this angiotensin fragment can enhance SARS-CoV-2 spike–AXL binding in vitro, while product specifications support controlled cardiovascular and renal research workflows.
-
Drosophila Keap1–Lamin Dm0 and Nuclear Architecture
2026-09-02
Carlson and colleagues identify a molecular and genetic interaction between Drosophila Keap1 and the B-type lamin Dm0, linking xenobiotic-response signaling to nuclear lamina organization and heterochromatin distribution. Their findings suggest that dKeap1 can influence developmental biology not only through transcriptional regulation, but also through higher-order chromatin architecture.
-
Amplex Red for Redox Assays in Wetland Research
2026-09-01
Amplex Red converts hydrogen peroxide formation into a sensitive fluorescence readout for oxidase, peroxidase, and oxidative stress studies. This guide translates new mangrove carbon-cycle findings into practical assay designs while emphasizing matrix controls, NADPH-system safeguards, and workflow-ready optimization.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-09-01
The reference study identifies Cdc2-like kinase 2 (CLK2) as a mediator of platinum resistance in ovarian cancer and links its activity to BRCA1 phosphorylation at Ser1423 and enhanced DNA damage repair. Its tissue, cellular, mechanistic, and xenograft evidence supports CLK2 as a candidate biomarker and therapeutic target, while also defining important limits for translating broad Clk inhibition into oncology.
-
Clarithromycin as a CYP3A Inhibitor
2026-08-31
Build reproducible CYP3A inhibition assays with Clarithromycin for drug-drug interaction research, statin metabolism interaction studies, and mechanistic pharmacokinetic studies. The workflow combines solvent control, pathway-specific comparisons, and the dabigatran evidence base to separate CYP3A-dependent effects from P450-independent disposition.
-
Amplex Red for Reliable Cell Redox Assays
2026-08-31
A scenario-driven guide to using Amplex Red (SKU C4839) for hydrogen peroxide detection, peroxidase activity, oxidative stress monitoring, and cell-based assay development. It explains compatibility controls, protocol parameters, interpretation limits, and vendor-selection considerations supported by product data and published HRP activity measurements.
-
AI-10-49 and the Transcriptional Logic of inv(16) AML
2026-08-30
CBFβ-SMMHC rewires RUNX1 activity in inv(16) acute myeloid leukemia, creating a mechanistically defined vulnerability. This thought-leadership guide explains how AI-10-49 connects direct oncoprotein disruption with chromatin recovery, MYCN/eIF4G1 biology, and a practical translational workflow.
-
DiI (DiIC18(3)) Membrane Probe Guide
2026-08-29
DiI (DiIC18(3)) provides orange-red labeling of plasma membranes in live or fixed cells and tissues, supporting membrane visualization, neuronal tracing, migration, fusion, adhesion, and lipoprotein workflows. Because it is insoluble in water and membrane localization can be affected by permeabilization, it should not be used as an aqueous-only stain or as an exclusive intracellular organelle marker.
-
Parathyroid hormone (1-34) (human) in CKD Assays
2026-08-28
Use Parathyroid hormone (1-34) (human) to connect rapid PTH receptor signaling with longer-term endothelial-to-mesenchymal transition and calcification phenotypes. This workflow emphasizes concentration-response design, serum calcium regulation controls, and practical troubleshooting for CKD valvular and bone metabolism research.
-
Angiotensin I: Mechanism, Evidence, and Research Use
2026-08-28
Angiotensin I is a decapeptide and the immediate precursor of angiotensin II in the classical renin-angiotensin system. Its defined sequence, enzymatic conversion, and research utility support cardiovascular disease mechanisms studies, enzyme assays, and antihypertensive drug screening.
-
Salvianolic Acid B: Rethinking Fibrotic Matrix Control
2026-08-27
A translational perspective on Salvianolic acid B as a research tool for studying LH2-linked collagen cross-linking, matrix stiffness, and pulmonary fibrosis progression.